Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18596818 | 0.97 | APLNR (0.38) | APLNRNR1I2PSMD14HSP90AA1MMP2 | |
| SCHEMBL23871060 | 0.97 | APLNR (0.38) | APLNRNR1I2PSMD14HSP90AA1MMP2 | |
| SCHEMBL18948485 | 0.97 | APLNR (0.38) | APLNRNR1I2PSMD14HSP90AA1MMP2 | |
| SCHEMBL18672471 | 0.95 | APLNR (0.37) | APLNRNR1I2PSMD14HSP90AA1MMP2 | |
| SCHEMBL25898707 | 0.95 | APLNR (0.37) | APLNRNR1I2PSMD14HSP90AA1MMP2 | |
| SCHEMBL20376381 | 0.94 | APLNR (0.38) | APLNRESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL19853068 | 0.90 | APLNR (0.40) | APLNRESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL19003492 | 0.90 | APLNR (0.41) | APLNRESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL21755153 | 0.84 | ESR1 (0.40) | APLNRNR1I2ESR1ESR2 | |
| SCHEMBL18948514 | 0.83 | ESR1 (0.41) | APLNRESR1ESR2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | APLNR 4570/4885NR1I2 1974/4885PSMD14 3001/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | APLNR 1127/4885NR1I2 2566/4885PSMD14 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.